PROF Financials

Income Statement
MetricQ3 2026Q2 2026Q1 2026Q4 2025Q3 2025
Revenue
9.8M
+295.9%
2.5M
-53.5%
5.3M
-10.7%
6.0M
+13.0%
5.3M
Cost of Revenue
2.1M
+301.1%
536.0K
-64.4%
1.5M
-24.2%
2.0M
+46.2%
1.4M
Gross Profit
7.7M
+294.5%
1.9M
-49.2%
3.8M
-4.0%
4.0M
+1.5%
3.9M
Operating Expenses
15.5M
+19.1%
13.0M
+9.8%
11.9M
+4.3%
11.4M
-11.6%
12.8M
R&D
5.8M
+2.7%
5.7M
+7.4%
5.3M
+23.2%
4.3M
-21.2%
5.4M
SG&A
9.7M
+31.7%
7.4M
+11.7%
6.6M
-7.0%
7.1M
-4.6%
7.4M
Operating Income
-7821000
+29.3%
-11066000
-38.0%
-8021000
-8.8%
-7369000
+17.3%
-8913000
EBITDA
-7688000
+29.7%
-10931000
-38.0%
-7921000
-9.1%
-7260000
+17.2%
-8766000
Net Income
-7722000
+19.1%
-9540000
-35.3%
-7053000
+13.7%
-8175000
-2.5%
-7977000
EPS (Basic)
$-0.21
+19.2%
$-0.26
-36.8%
$-0.19
+29.6%
$-0.27
-3.8%
$-0.26
EPS (Diluted)
$-0.21
+19.2%
$-0.26
-36.8%
$-0.19
+29.6%
$-0.27
-3.8%
$-0.26
Shares (Diluted)
36.6M
+0.6%
36.4M
+0.1%
36.3M
+18.1%
30.7M
+2.1%
30.1M
Profound Medical (PROF) — Financials